The U.S. Navy needs more firepower.

At the start of last year, it only had 296 battle-force ships. But by 2031, it wants a 450-ship fleet... made up of 299 warships, 68 auxiliary ships, and 83 unmanned vessels.

The pressure is on the U.S. to grow its naval fleet. Not only is its current force stretched too thin, but it's also now behind China in number of battle-force ships.

As competition with China intensifies, America will need more ships to deter conflict in the Indo-Pacific region, particularly around Taiwan and the South China Sea.

Part of the Navy's expansion plan is to order 15 nuclear-powered battleships from U.S. shipyards by 2055.

Nuclear-powered ships are much more efficient than standard ships. A tiny amount of nuclear fuel provides massive amounts of energy compared with heavy fuels like oil or diesel. And nuclear reactors can operate for 25 to 30 years – or even longer – without needing to refuel.

Billions of dollars are going to be spent each year to build a bigger, better naval fleet... That should get investors excited.

Most folks will probably look to invest in traditional shipbuilders. But building a warship is a brutal, low-margin grind. Labor shortages, fixed-price contract overruns, and supply-chain delays can wipe out profits before a ship even hits the water.

There's a better play...

You don't need to gamble on which shipbuilder will win the next contract. Instead, you can own the mandatory "tollbooth" that every single nuclear ship must clear before it reaches the ocean.

That tollbooth is BWX Technologies (BWXT).

BWX is the sole manufacturer of nuclear reactors for the U.S. Navy's nuclear-powered fleet, including Nimitz- and Ford-class carriers and Virginia-class submarines. The company makes nuclear reactors, heat exchangers, and steam generators.

The Navy is a huge customer in BWX's government-operations segment. It has been for more than 70 years. Today, about two-thirds of sales come from its naval nuclear-propulsion segment.

The U.S. Navy cannot build a single nuclear warship without BWX. Period.

That moat delivers unprecedented financial visibility for shareholders. BWX's multiyear backlog recently surged past $8.6 billion, locking in guaranteed revenue as the Navy ramps up its order book.

Supported by steady defense spending and expanding commercial nuclear operations, there are countless reasons to be bullish on BWX.

If you're a serious, long-term-focused investor, you should consider adding BWX to your portfolio.

Of course, the question is... When should you buy?

BWX is up nearly 200% over the past five years. Shares trade at a premium valuation, which makes sense because of the company's backlog.

However, the stock has been in a steady downtrend since mid-April, falling about 28%.

Will the stock bounce back soon and continue its longer-term trend higher... or will it keep moving lower?

For the answer, we can turn to my new StockTracker tool.

In general, the market moves in cycles. Sectors and stocks come into favor for a time and outpace the market, then fall back a bit as others catch up. As a result, stocks rotate in a predictable fashion, round and round again, in a pattern that looks a lot like this...

My StockTracker tool shows where a stock or sector is on this graph. And my research has pinpointed exactly where you want stocks to be on this chart. We call it the "Buy Zone," which is represented by the green circle in the chart below.

You'll want to avoid buying stocks that are turning lower in the "Topping" quadrant or are in the "Bearish" quadrant.

Let's look at where BWX is today...

As you can see, BWX isn't in the Buy Zone just yet... but it's close. (Each dot represents a week.)

When BWX does move into the Buy Zone, then we'll know the bottom is in. And from that point on, the stock should start to outperform the S&P 500 Index.

So you shouldn't rush to buy BWX today. Instead, you should keep an eye on our StockTracker to see when it's time to pull the trigger.

The StockTracker is a powerful tool. No matter what stock or fund you're interested in buying, you should check where it's positioned on my chart. That way, you can make sure you're buying it at the right time.

To learn more about my easy-to-use system and how it can help you maximize your gains, click here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
August 5, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top